Teva (TEVA) and Antares (AIS) Announce FDA Approval of Needle-Free Injector for Tev-Tropin(R)
More News related to AIS
- Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
- Antares Pharma Enters into License and Asset Purchase Agreements with Ferring
- Antares Pharma (AIS) Reports a Q3 Loss In-line W/Estimates
- Antares Pharma Reports Third Quarter 2009 Financial and Operating Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
More News related to TEVA
- Unusual 11 Mid-Day Movers 12/01: BIOF, ZN, GSIT, CAGC, RDN Higher; STAA, LTON, ZOOM, OVTI Lower
- Morning Movers 12/01: PEIX, SYMX, GSIT, HDY, GES, BPFH Higher; LTON, OVTI, PLX Lower
- Teva Pharma (TEVA) Submits BLA to U.S. FDA for XM02
- Teva Pharma (TEVA) and Codexis Sign Second Agreement This Year
- Protalix (PLX) Sells-Off On Pfizer News, As Fast Money Disappointed In No Takeover
More News related to Corporate News
- AEterna (AEZS) Announces FDA Fast Track Status for KRX-0401
- Keryx (KERX) Granted FDA Fast Track Designation for KRX-0401
- Dyax (DYAX) Receives FDA Approval of KALBITOR(R) for Treatment of Acute Attacks of Hereditary Angioedema
- Santarus (SNTS) Earns $20 Million Milestone on FDA Approval for NDA of ZEGERID
- Santarus (SNTS) Jumps Ahead of Expected News
Earlier this morning, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and its partner, Antares Pharma, Inc. (Amex: AIS) today announced the approval of a Supplemental New Drug Application, which added "needle-free injection" to its Tev-Tropin(R) [somatropin for injection] brand human growth hormone drug label. Teva will market the Antares needle-free device as the Tev-Tropin Tjet Injector system.
Shares of Antares have spiked about 60% on the news today. The stock is seeing extremely heavy volume: already has more than 9.5 million shares, which compares to its 30-day average volume of 157,000 shares.
Related Categories
Corporate NewsStocks Mentioned
+0.00Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
what is this? ais at $25.12???
Ross D on Jul 4, 2009 05:25 PMis this for real? not even funny if not!